Private CRO Rho inked its largest-ever federal contract, signing a 7-year deal with the U.S. National Institutes of Health that will pay out about $16.5 million each year.
Researchers at the University of California, Berkeley, have identified a viral protein that causes fluid loss and shock that indicate severe and potentially fatal dengue infections.
Immunotherapy developer Agenus, looking to further invest in its immuno-oncology pipeline, plans to temporarily cash out of a deal with GlaxoSmithKline to grab $115 million in exchange for royalties it once held on an adjuvant for GSK's malaria and shingles vaccines.
MorphoSys is set to ratchet up investment in R&D as it seeks to push candidates through late-phase trials and win the approvals that will allow it to evolve into a fully integrated biopharma company. The additional funds will support the startup of 5 new trials over the next 15 months.
Researchers have long searched for ways to track cancer cells as they proliferate and stop them from spreading. Now, scientists in the U.S. are developing a spongelike device that can mop up cancer cells as they move through the body, potentially offering an early warning sign to doctors.
After suffering back-to-back R&D and franchise setbacks, Biogen is beefing up its pipeline with a late-stage autoimmune drug, handing over $60 million in cash and promising up to $484 million in milestones to complete the pact with Mitsubishi Tanabe.
Startup Cofactor Genomics is getting in on the consumer testing craze, developing an innovative RNA-based diagnostic to cash in on a rapidly growing market and challenge business models laid out by rivals.
Bristol Myers-Squibb, a leader among companies at work in immuno-oncology, is pressing for wider use of its lead treatment with new data showing the injected drug could succeed as part of a first-line treatment in lung cancer.
Chronic pain giant Purdue Pharma signed a deal worth as much as $213 million to get its hands on a VM Pharma treatment that could widen the company's portfolio beyond traditional opioid drugs.
Long-troubled drug developer Geron is touting what it calls "unprecedented" early results for its lead cancer drug, sending the biotech's share price up as it moves forward with partner Johnson & Johnson.